Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis

Table 1

Patient characteristics.

Cohort characteristics	Number	%
Age distribution
20–30	5	3%
31–40	6	4%
41–50	15	9%
51–60	34	20%
61–70	40	24%
71–80	38	23%
81–90	24	14%
>90	5	3%
Mean age	65.2
Gender
Male	86	51.50%
Female	81	48.50%
Distribution by malignancy
Breast	15	9%
GI	19	11%
Gyn	10	6%
Colorectal	14	8%
Lung	23	14%
Hematologic	41	25%
Prostate	13	8%
Renal cell	5	3%
Skin	3	2%
Urothelial	8	5%
Head/neck	6	4%
Other	10	6%
Type of anticoagulation
Coumadin	1	1%
Dalteparin	152	91%
Enoxaparin	5	3%
Fondaparinux	7	4%
None	2	1%